IMR.F AC IMMUNE SA SF-02
- Market cap
- EUR 191M
- P/E
- -
- P/B
- 6.77x
- ROE
- -107.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMR.F undervalued?
Graham numberThe Graham number of AC IMMUNE SA SF-02 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AC IMMUNE SA SF-02 fundamental analysis
No fundamental analysis for AC IMMUNE SA SF-02 yet.
AC IMMUNE SA SF-02 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab…
Full company profileAC IMMUNE SA SF-02 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AC IMMUNE SA SF-02 annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 3.94M | 14.8M | 27.3M | 3.57M | 26.0M |
| Operating Income | -79.0M | -70.8M | -53.6M | -52.4M | -68.9M | -31.2M |
| EBITDA | - | -68.0M | -51.8M | -48.6M | -67.8M | -28.7M |
| Net Income | -73.0M | -70.8M | -54.2M | -50.9M | -70.4M | -28.9M |
| EPS | -0.87 | -0.85 | -0.55 | -0.51 | -0.69 | -0.29 |
| Balance Sheet | ||||||
| Total Assets | 261M | 186M | 183M | 231M | 154M | 139M |
| Total Liabilities | 29.5M | 16.9M | 22.2M | 119M | 109M | 112M |
| Shareholders' Equity | 232M | 169M | 161M | 112M | 44.9M | 26.9M |
| Cash & Short-term Investments | 82.2M | 31.6M | 78.5M | 36.3M | 26.8M | 18.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -65.7M | -73.6M | -60.4M | 65.8M | -69.3M | - |
| Capital Expenditure | 2.64M | 1.24M | 801K | 576K | 900K | 0.00 |
| Free Cash Flow | -68.3M | -74.8M | -61.2M | 65.3M | -70.2M | - |
| Ratios | ||||||
| ROE | -31.5% | -41.9% | -33.8% | -45.4% | -157.0% | -107.3% |
| ROA | -27.9% | -38.1% | -29.7% | -22.0% | -45.7% | -20.8% |
| Net Profit Margin | - | -1,798.0% | -366.4% | -186.4% | -1,971.6% | -111.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AC IMMUNE SA SF-02 dividends
AC IMMUNE SA SF-02 has not paid dividends in the last 5 fiscal years.
Who owns AC IMMUNE SA SF-02
- Insiders 38.09%
- Institutions 24.35%
- Public & others 37.56%
- Shares outstanding 99.4M
- Free float 26.5M
AC IMMUNE SA SF-02 company profile
- Company name
- AC IMMUNE SA SF-02
- Ticker
- IMR.F
- ISIN
- CH0329023102
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 90
- Fiscal year end
- December
- Address
- Building B, Lausanne, Switzerland, 1015
- Phone
- 41 21 345 91 21
- Website
- acimmune.com
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
AC IMMUNE SA SF-02 management
10- Mr. Christopher RobertsCFO & VP of Finance · born 1989
- Mr. Piergiorgio DonatiChief Operating Officer · born 1971
- Dr. Martin Zugel M.D., Ph.D.Interim CEO & Chairman of the Board · born 1963
- Dr. Gary Anthony Waanders Ph.D.Senior VP of Investor Relations & Corporate Communications · born 1964
- Dr. Matthias Maurer Ph.D.Senior VP & General Counsel · born 1982
- Dr. Oliver Sol M.D.VP & Head of Clinical Development · born 1967
- Dr. Julien Rongere Ph.D.Senior Vice President of Regulatory Affairs & Quality Assurance · born 1978
- Mr. Mark DantonExecutive Vice President of Information Systems & Artificial Intelligence · born 1964
- Dr. Günther Staffler Ph.D.Executive Vice President of Development · born 1969
- Dr. Francesca CapotostiSenior Vice President of Research